On November 30, 2021, SOPHiA GENETICS SA restructured its executive management team to include the following individuals, each of whom is an executive officer of the Company: Jurgi Camblong, Chief Executive Officer; Ross Muken, Chief Financial Officer; Daan van Well, Chief Legal Officer; Manuela da Silva Valente, Chief People Officer; Zhenyu Xu, Chief Scientific Officer; Philippe Menu, Chief Medical Officer. The biographies of Jurgi Camblong, Ross Muken and Daan van Well were included in the Company's prospectus dated July 22, 2021, filed with the U.S. Securities and Exchange Commission pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended. The biographies of Manuela da Silva Valente, Zhenyu Xu and Philippe Menu are set forth below: Manuela da Silva Valente, Badership roles at IQVIA (formerly Quintiles and IMS Health Inc.), including as Global Senior Director of Human Resources from 2016 to 2018. Zhenyu Xu, Ph.D., age 39, has served as Chief Scientific Officer since May 2014. Dr. Xu joined in 2012 and served as Director of Bioinformatics until his appointment as Chief Scientific Officer and was the leader of the technology team that developed SOPHiA platform. Philippe Menu, M.D., Ph.D., M.B.A., age 40, has served as Chief Medical Officer since February 2020. From 2011 to 2020, Dr. Menu was a management consultant with McKinsey & Company, focusing on the biopharmaceutical sector and in particular innovative therapies and diagnostics in oncology and rare diseases. In addition, on November 30, 2021, the Company announced that Bram Goorden, the Company's Chief Operating Officer, will depart the Company on May 31, 2022 to pursue a new opportunity. Bram Goorden will be on gardening leave until his departure from the Company.